-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
| New findings from CUHK research provide new directions for the treatment of cerebellar atrophy |
China News Service, Hong Kong, February 28 (Reporter Han Xingtong) The Chinese University of Hong Kong (CUHK) announced on the 28th that the CUHK team recently cooperated with the University of Oxford in the United Kingdom and found that antagonism between proteins is involved in genetic ataxia and neurodegenerative diseases The function in cerebellar atrophy is expected to provide a new direction for intervention in type III treatment of cerebellar atrophy.
Hong Kong Hong Kong
In populations around the world, including the Mainland and Hong Kong , cerebellar atrophy type III (also known as Machado Joseph’s disease) is the most common type of cerebellar ataxia disease with dominant genetic inheritance.
Hong Kong
Professor Chen Haoran from the School of Life Sciences, CUHK and his research team recently collaborated with the University of Oxford in the UK and found that the antagonism between proteins can regulate the disease protein degradation and neurodegeneration of hereditary ataxia, which is expected to be used for the study of neurodegenerative diseases Treatment brings new directions.
Chen Haoran said that this study revealed the complex protein antagonism between Prpf19 and Exoc7 proteins, and further studies on the mechanism of protein network controlling protein aggregation will help the research team develop potential molecules or activators for Prpf19, hoping to help the cerebellum Atrophy type III and other neurodegenerative diseases provide new treatment options.
